ReviewSeminars in cancer biology2017
TGFΒ-induced transcription in cancer.
Review in Seminars in cancer biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 126 citations in OpenAlex.
- Rho GTPase-related prognostic signature for esophageal squamous cell carcinoma identifies CTTN as a candidate adverse prognostic marker.Molecular biology reports · 2026Article
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation.Frontiers in immunology · 2026Review
- KY216-tubulin complex captures VASH2 to inhibit NSCLC metastasis.Nature communications · 2025Article
- Long non-coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application.FEBS open bio · 2025Review
- Multi-omics profiling of TGF-β isoforms and regulatory miRNAs in astrocytic tumors reveals TGF-β-3 as a prognostic biomarker.Frontiers in oncology · 2025Article
- Sarcomatoid carcinoma of the pancreas (Review).Oncology letters · 2024Review
- Review
- Review
- TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll-like-receptor signalling.International journal of experimental pathology · 2024Article
- Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms.Frontiers in immunology · 2024Review
- Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.BMC gastroenterology · 2023Article
- Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma.International journal of molecular sciences · 2023Article
- Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- TGF-beta signal transduction: biology, function and therapy for diseases.Molecular biomedicine · 2022Review
- Knockdown of RhoQ, a member of Rho GTPase, accelerates TGF-β-induced EMT in human lung adenocarcinoma.Biochemistry and biophysics reports · 2022Article
- Golgi scaffold protein PAQR3 as a candidate suppressor of gastric cardia adenocarcinoma via regulating TGF-β/Smad pathway.Journal of clinical laboratory analysis · 2022Article
- Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-β pathway.Cancer gene therapy · 2022Article
- The role of long non-coding RNAs in the pathogenesis of head and neck squamous cell carcinoma.Molecular therapy oncolytics · 2022Review
- TGF-β1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?BMC cancer · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The Transforming Growth Factor-beta (TGFβ) pathway mediates a broad spectrum of cellular processes and is involved in several diseases, including cancer. TGFβ has a dual role in tumours, acting as a tumour suppressor in the early phase of tumorigenesis and as a tumour promoter in more advanced stages. In this review, we discuss the effects of TGFβ-driven transcription on all stages of tumour progression, with special focus on lung cancer. Since some TGFβ target genes are specifically involved in promoting metastasis, we speculate that these genes might be good targets to block tumour progression without compromising the tumour suppressor effects of the TGFβ pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.